Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPTi with Sulfadoxine-Pyrimethamine in Children
NCT00168948Phase 4
Key facts
- Status
- Unknown
- Start
- Mar 2003
- Sponsor
- Charité – Universitätsmedizin Berlin
- Modality
- Small Molecules
- Conditions
- malariaanemia
01
Overview
Phase 4, randomised, double-blind trial in malaria and anemia comparing Sulfadoxine-Pyrimethamine with Placebo (2 arms). Primary endpoints: Incidence of malaria attacks at 24 months, Impact on anemia at 24 months and 1 more. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Sulfadoxine-Pyrimethamine
Intermittent Preventive Treatment with SP
Placebo
Placebo
03
Who it enrols
Infants >2 months of age with no concomitant serious disease and no allergy to sulfonamides.
04
Endpoints
Primary
Incidence of malaria attacks
Impact on anemia
Efficacy and safety of IPTi with SP
Secondary
Influence on parasite multiplicity
Impact on child development
Beyond the preview
Go deeper on NCT00168948.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168948.